Chondrometrics

What Chondrometrics does

Chondrometrics GmbH is a German Contract Research Organization (CRO) founded in 2003/2004 as a spin-off of Ludwig-Maximilians-Universität (LMU) München and headquartered in Freilassing, near Salzburg. The firm provides quantitative MRI-based imaging biomarker analysis services to pharmaceutical companies conducting osteoarthritis clinical trials and to academic research institutions studying joint pathology. Its core service offering centers on extracting validated imaging biomarkers — including cartilage thickness, cartilage T2 composition, meniscus morphology and position, bone/muscle/adipose tissue morphology, infrapatellar fat pad radiomics, and synovitis morphology — from MRI scans of human and animal joints. The underlying technology combines quality-controlled manual gold-standard analysis with AI (convolutional neural network) based fully automated segmentation that has been technically and clinically validated against the manual reference.

The firm operates a Class IIa Medical Device software platform certified under EU MDR 2017/745 Annex IX, with an EN ISO 13485:2021 certified Quality Management System that is also compliant with Good Clinical Practice (GCP) and US 21 CFR Part 11 standards, making its output directly usable in regulatory submissions for disease-modifying osteoarthritis drugs (DMOADs). Its go-to-market is direct enterprise sales to pharmaceutical sponsors of late-stage DMOAD trials (including the FORWARD trial for sprifermin and the ROCCELLA trial for GLPG1972), supplemented by research collaborations with leading academic centers across at least nine countries. The firm has completed over 10 industry-sponsored clinical trials and more than 60 funded academic grants, accumulating a dataset of 50,000+ analyzed joints, 200+ journal publications, and 40,000+ citations (h-factor >100) that constitute the primary moat and demand-generation engine. Distribution is direct, with no disclosed channel partners; pricing is custom B2B contract-based and not publicly disclosed. The firm is privately held with no external investors or parent company reported in the available data. As of January 1, 2026, Wolfgang Wirth succeeded founder Felix Eckstein as CEO, and a refreshed corporate website was launched in February 2026.

Name

Chondrometrics

Legal name

Chondrometrics GmbH

Website

https://chondrometrics.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Chondrometrics GmbH is a German CRO providing quantitative MRI-based imaging biomarker analysis services for osteoarthritis clinical trials and academic research, serving pharmaceutical sponsors of DMOAD development and university research centers across nine countries.

Ownership category

akta.pro rank

Product category

Medical Imaging CRO Services (Osteoarthritis Imaging Core Lab)

NAICS

Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industry

Medical Imaging AI (HDAAAEAH)

Keywords

• Quantitative MRI imaging
• Osteoarthritis imaging biomarkers
• Clinical trial imaging services
• Cartilage segmentation analysis
• Medical image analysis

Headquarters

HQ city

Freilassing

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Clinical Trial Imaging Services: Providing quantitative MRI imaging biomarker analysis services for pharmaceutical company-sponsored clinical trials evaluating disease-modifying osteoarthritis drugs (DMOADs). Services include baseline and longitudinal cartilage measurements for regulatory submissions.
2. Academic Research Collaborations: Research collaborations and subcontracts with academic institutions conducting osteoarthritis imaging research, funded by grants from various countries.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Chondrometrics provides quantitative MRI-based medical image analysis services for osteoarthritis research and structure-modifying clinical trials. Using a Class IIa Medical Device software platform (EU MDR 2017/745) and AI/CNN-based automated segmentation, the company delivers validated imaging biomarkers — including cartilage morphology (thickness), cartilage composition (T2), meniscus morphology and position, bone/muscle/adipose tissue morphology, IPFP radiomics, and synovitis morphology — to pharmaceutical sponsors of DMOAD trials and to academic research collaborators.

Product overview

Chondrometrics offers a Class IIa Medical Device software platform (EU MDR 2017/745) providing quantitative imaging biomarker analysis services for osteoarthritis research and clinical trials. The company's core service involves analyzing MRI scans to extract quantitative biomarkers including cartilage morphology (thickness), cartilage composition (T2 relaxation time), meniscus morphology and position, bone morphology, muscle and adipose tissue morphology, infrapatellar fat pad (IPFP) radiomics, and effusion synovitis morphology. The company utilizes quality-controlled manual gold-standard analysis combined with technically and clinically validated, fully automated segmentation using AI (CNN) technology to deliver scalable, cost-effective analysis for structure-modifying clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Quantitative MRI Imaging Biomarker Analysis Services for Osteoarthritis Medical image analysis service providing quantitative MRI-based biomarkers of articular tissues — cartilage morphology (thickness), cartilage composition (T2 relaxation time), meniscus morphology and position, bone/muscle/adipose tissue morphology, infrapatellar fat pad (IPFP) radiomics, and (effusion) synovitis morphology — for pharmaceutical-sponsored DMOAD clinical trials and academic osteoarthritis research, executed on a Class IIa Medical Device software platform (EU MDR 2017/745) with AI/CNN-based automated segmentation validated against quality-controlled manual gold-standard analysis.

Quantifiable outcome

• Clinical validation of automated AI-based cartilage segmentation matching manual gold-standard accuracy
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered major, core and minor.

• IHI-PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation)majorStrategic or Co-development Partner · 1 December 2025European consortium project launched December 2024, Chondrometrics contributing to all six workpackages on big data evaluation for OA endpoints.
• IMI-APPROACH (Applied Public-Private Research enabling OsteoArthritis Clinical Headway)majorStrategic or Co-development Partner · 1 January 2019European Innovative Medicines Initiative project designed to improve stratification in osteoarthritis, resulting in multiple publications between 2022-2025.
• Paracelsus Medical University (PMU) SalzburgcoreStrategic or Co-development PartnerLong-standing research partnership with PMU Salzburg including joint Salzburg Leopoldina Symposium, research program for imaging, and PhD programs. Multiple co-authored publications and collaborative research projects.
• University of BaselcoreStrategic or Co-development PartnerOA-BIO Eurostars consortium collaboration with Annegret Mündermann and Simon Herger on cartilage T2 and thickness analysis using qDESS MRI and automated segmentation.
• Universitätsmedizin BerlinmajorStrategic or Co-development PartnerPROTO Horizon project collaboration on rapid MRI acquisition protocols for assessing multiple articular tissues, with Nicholas Brisson, Georg Duda, Tazio Maleike, and Tobias Winkler.
• Stanford UniversitymajorStrategic or Co-development PartnerCollaboration with Akshay Chaudhari on comparison of MRI sequences for cartilage thickness analysis using deep learning AI algorithms.
• University of SydneymajorStrategic or Co-development PartnerCollaboration with David Hunter and team on osteoarthritis imaging research, including visits and joint publications.
• FNIH OA Biomarkers ConsortiumcoreStrategic or Co-development PartnerFoundation for the National Institutes of Health consortium for identifying and qualifying biomarkers to support OA drug development. PROGRESS OA study phase for external validation of prognostic biomarkers.
• Eurostars OA-BIO ConsortiumcoreStrategic or Co-development PartnerEurostars funded project for automated laminar cartilage T2 relaxation time analysis, successfully completed with multiple publications on technical and clinical validation.
• Southern Medical University GuangzhouminorStrategic or Co-development PartnerOsteoarthritis research delegation from China visiting Chondrometrics office to explore collaborations.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• ICON plc: Top-tier global CRO with imaging biomarker and centralized imaging core lab capabilities inherited via the PRA Health Sciences merger. Competes for the same pharma-sponsored imaging endpoint contracts as Chondrometrics, but as one component of a much larger CRO service portfolio.
• IQVIA: Largest global CRO and clinical research services firm, with significant imaging and biomarker capabilities supporting late-stage pharmaceutical trials. Differs from Chondrometrics in scale and breadth but competes for the same budget pool when sponsors select an imaging endpoint partner for OA trials.

Direct peers

• Medpace: Mid-sized full-service CRO with a dedicated imaging core lab providing centralized MRI and biomarker read services for global clinical trials. Overlaps directly with Chondrometrics in musculoskeletal and OA imaging endpoints but competes as part of a much broader CRO offering.
• Clario: Global imaging core lab and clinical trial endpoint services provider resulting from the merger of BioClinica and eResearch Technology, including the legacy VirtualScopics imaging biomarker business. Clario operates the same imaging endpoint model for musculoskeletal and other indications, making it Chondrometrics' most direct large-scale competitor for OA trial contracts.
• IXICO plc: UK-based specialist imaging biomarker CRO providing quantitative MRI analysis services for clinical trials in neurological and other indications. Closely comparable business model to Chondrometrics — niche imaging biomarker services for pharma R&D — with overlap on musculoskeletal and joint imaging endpoints.
• Image Analysis Group (IAG): Specialty imaging core lab and image analysis CRO supporting pharma and medical device clinical trials across multiple therapeutic areas. Directly comparable model to Chondrometrics, providing quantitative imaging biomarker read services with AI-enabled workflows.

Emerging players

• Arterys: Cloud-native medical imaging AI platform enabling automated quantification and analysis of MRI and CT studies. Overlaps Chondrometrics' CNN-based image analysis layer as a technology adjacency, though Arterys is broader in modality and has less OA-trial-services focus.
• Quibim: Valencia-based imaging biomarker platform using AI to extract quantitative imaging features for research and clinical use across oncology, neurodegeneration and musculoskeletal disease. Overlaps Chondrometrics in AI-driven MRI biomarker analysis, particularly for musculoskeletal and joint indications.
• Median Technologies: French-listed medical imaging AI and CRO company providing iCRO imaging analysis services for oncology-focused clinical trials, with expansion into broader therapeutic areas. Comparable to Chondrometrics in providing AI-powered image quantification read services for pharma-sponsored trials.

Regional players

• BioTel Research: US-based clinical research and imaging services organization with imaging core lab capabilities supporting cardiology, neurology and musculoskeletal trials. Comparable model for delivering imaging endpoint analyses to pharma sponsors, primarily serving North American trial sites.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/chondrometrics-gmbh

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chondrometrics